Abstract Appearance concerns are common among HIVinfected individuals, and previous cross-sectional and longitudinal data indicate that these concerns are associated with antiretroviral therapy (ART) non-adherence. However, to date, no known prospective data have explored the mechanism behind this relationship. Thus, the aim of the current study was to test depression severity as a prospective mediator of the relationship between appearance concerns and ART non-adherence in HIV-infected individuals with a history of injection drug use (IDU). Participants were 89 HIV-infected individuals with a history of IDU who participated in a prospective, randomized controlled trial of cognitive behavioral therapy for depression and medication adherence. Clinician-administered measures of depression severity and appearance concerns, along with electronic monitoring of ART non-adherence were included. Data were analyzed using longitudinal linear mixed-level modeling, and mediation was tested via the Monte Carlo Method of Assessing Mediation. Appearance concerns were predictive of depression severity, c = .31, SE = .076, 95 % CI [.16, .46], t = 4.1, p = .0001, and depression severity was predictive of ART non-adherence, c = 3.3, SE = 1.3, 95 % CI [.8, 5.8], t = 2.6, p = .01. The effect of appearance concerns on ART non-adherence, however, was significantly mediated by depression severity, c = 1.02, 95 % CI [.21, 2.1]. Appearance concerns are associated with depression severity, which in turn is associated with ART non-adherence. Integrative interventions addressing appearance concerns, depression and ART adherence are needed, as this is one potential pathway towards worse health outcomes in HIV-infected individuals.
Introduction
Appearance concerns are common among HIV-infected individuals, with studies indicating that nearly one third of HIV-infected men and one half of HIV-infected women are dissatisfied with their bodies (Sharma et al., 2006 (Sharma et al., , 2007 . Appearance-related concerns comprise a significant stressor for HIV-infected individuals (Blashill & Vander Wal, 2010; Huang et al., 2006; Marín et al., 2006; Santos et al., 2005; Tate & George, 2001; Theodore et al., 2011) . One factor that can lead to appearance concerns among this population is changes in adipose tissue distribution, known generally as lipodystrophy (Huang et al., 2006; Marín et al., 2006; Sharma et al., 2006 Sharma et al., , 2007 . This condition is associated with both HIV disease progression (Giralt et al., 2006) as well as sustained adherence to ART (Ammassari et al., 2002; Marín et al., 2006) . Sixty percent of individuals experience moderate or severe changes in body fat (Guaraldi et al., 2008) , including lipoatrophy (e.g., in the face, arms, legs, and/or buttocks) and/or lipohypertrophy (e.g., in the stomach, back of the neck, and/or breasts). Despite the high prevalence of appearance concerns among HIV-infected individuals, few studies have explored this construct among HIV-infected IDU (e.g., Blashill et al., 2012) , representing a notable gap in the literature. Perhaps this gap is due to beliefs that self-care behaviors among HIV-infected IDU are overwhelmingly explained by their drug use, and thus, additional explanatory variables, such as psychosocial concerns, may be overlooked (e.g., Spire et al., 2007) . Given that the majority of research on appearance concerns in HIV-infected individuals has focused on men who have sex with men (MSM), it is important to determine if this construct is similarly salient among IDU.
Although the advent of modern antiretroviral therapy (ART) in the late 1990s transformed HIV from a lifethreatening disease into a chronic, manageable condition, HIV-infected individuals must maintain high levels of adherence in order to reap optimal treatment benefits (e.g., 95 % adherence for traditional antiretroviral medications, Low-Beer et al., 2000; Paterson et al., 2000 ; and 80 % for newer boosted protease inhibitors, Kobin & Sheth, 2011; Martin et al., 2008) . Unfortunately, studies utilizing electronic pill caps have found that the average rates of adherence for HIV-infected individuals on ART regimens seem to be between 56 % and 65 % (Bangsberg et al., 2001 , Genberg et al., 2012 Liu et al., 2001) . Identifying possible psychosocial variables that impact adherence is crucial for both the treatment and prevention of HIV, as those with suppressed viral loads confer a significantly diminished risk of transmitting the disease to others (for a recent review, see Ambrosioni et al., 2011) . This may be particularly salient for depressed IDU who are HIVinfected, as these characteristics predict suboptimal ART adherence that persists even throughout methadone treatment (Carrieri et al., 2003; Avants et al., 2001) .
Importantly, appearance-related concerns have been associated with self-reported ART non-adherence, both cross-sectionally (Corless et al., 2005) , as well as longitudinally (Ammassari et al., 2002; Duran et al., 2001; Glass et al., 2010; Plankey et al., 2009) ; however, there is a paucity of research explaining the mechanism behind this relationship. One possible mediator of the link between appearance concerns and ART non-adherence is depression. Appearance related concerns have been associated with depression in HIV-infected individuals (Marín et al. 2006; Sharma et al., 2006 Sharma et al., , 2007 . Moreover, depression has been related to non-adherence, with a recent meta-analysis of 95 studies finding that those with depression were significantly less adherent to ART regimens than those without depression (Gonzalez et al., 2011) . Given the bivariate relationships between depression and both appearancerelated concerns and ART non-adherence, further examination of the mechanistic effect depression has on non-adherence in the context of appearance concerns is warranted.
Our prior work is the only study we know of that has tested the relationship between depression, body dissatisfaction, and ART non-adherence (Blashill & Vander Wal, 2010) . In this cross-sectional study, self-reported depression mediated the relationship between body dissatisfaction and self-reported non-adherence among HIVinfected MSM with high levels of body dissatisfaction. Nevertheless, the cross-sectional nature of this study precludes temporal inferences inherent to properly assessing mediational models (e.g., Kraemer et al., 2008) . The current research builds on the existing literature by assessing, prospectively, over a 1 year period, the relationships between appearance concerns, ART non-adherence, and depression severity. Moreover, rather than rely on participant self-report data, we introduce objectively measured adherence measures through electronic pill cap monitoring, as well as a clinician-administered assessment of depression severity and appearance concerns. Given the literature to date, it was hypothesized that depression severity would significantly mediate the relationship between appearance concerns and ART non-adherence (Fig. 1) .
Method

Participants
Participants were 89 HIV-infected individuals with comorbid depression, between the ages of 18 and 65, who were receiving treatment for opioid dependence. The current study is a secondary analysis of data from a randomized controlled efficacy trial investigating the use of cognitive behavioral therapy (CBT) for treating depression and enhancing ART adherence in those living with HIV. Enrollment occurred between July 2005 and October 2008. All participants were diagnosed with current or subsyndromal depressive disorder, were prescribed antiretroviral therapy, had a history of injection drug use, and were in opioid treatment during the past month (for more exhaustive study details, please see Safren et al., 2012) . Sample characteristics are portrayed in Table 1 . Participants were recruited through methadone treatment clinics, community outreach, and HIV clinics in the greater Boston area. All participants received a complete description of the study and provided written informed consent, and all study procedures were approved by the IRBs at Massachusetts General Hospital in Boston and Rhode Island Hospital in Rhode Island. Participants were seen for four major assessment visits over the course of the study, a baseline assessment (TI), 3 months from baseline (T2), 6 months from baseline (T3), and 12 months from baseline (T4). At each of these visits, participants completed clinician-administered measures of depression severity and physical symptoms related to HIV infection, as well as electronic pill cap evaluations for non-adherence (MEMS; Medication Event Monitoring System; AARDEX).
Measures
ART non-adherence
Participants were assigned a MEMS cap to use with the antiretroviral medication they were prescribed to use most frequently or reported having the most difficulty remembering to take. The MEMS cap recorded each time the bottle was opened; however, to account for doses that participants may have taken without using the bottle (e.g., if participants took out afternoon doses for later when they opened the bottle in the morning), doses were also counted as taken if participants could recount specific times in which they took their medications but did not use the pill cap (Liu et al., 2001 (Liu et al., , 2006 Llabre et al., 2006) . This multiple method approach to measuring adherence has been found to increase the validity of adherence assessment (see Llabre et al., 2006) . Although MEMS is an objective indicator, adherence may be underestimated if the MEMS cap is not used. Thus, using a corrected adherence score that accounts for doses taken without opening the bottle mitigates this concern. A dose was counted as missed if it was not taken within ±2 hours of a previously designated target time (Applebaum et al., 2009; Safren et al., 2009 Safren et al., , 2012 . One was subtracted from percent of adherence for purposes of converting the variable from an adherence metric to a non-adherence metric. This approach was taken to enhance the interpretability of the indirect effect (see below). That is, all relevant mediation variables (i.e., appearance concerns, depression severity, and ART nonadherence) were coded in a fashion that allowed higher scores to reflect poorer outcomes.
Depression severity
Clinicians rated the Clinical Global Impression (CGI) of severity, a rating of distress and impairment for depression on a scale from 1 (not ill) to 7 (extremely ill; NIH, 1985) . In order to maximize measure validity, CGI scores were reviewed during audiotape supervision meetings with a licensed clinical psychologist. The CGI has been found to have strong convergent validity (r [ .85) with other measures of depression, such as the Montgomery-Asberg Depression Rating Scale and Hamilton Depression rating scale (e.g., Leon et al., 1993; Müller et al., 2003) . Percentages do not always sum to 100 due to overlap or some participants reporting more than one demographic category
Appearance-related HIV symptoms
At each visit, a clinician administered the 20-item ACTG Symptoms Distress Module (Justice et al., 2001) , which assesses symptoms commonly reported among those on antiretroviral regimens. The measure asks participants to indicate whether they had each symptom during the past 4 weeks and to what extent it bothered them on a five-point scale (i.e., ''0-I do not have this symptom''; ''4-I have this symptom and it bothers me a lot''). Three of these items were appearance-related and assessed weight gain, weight loss, and hair loss. Specifically, items asked if participants had noticed ''changes in the way your body looks such as fat deposits or weight gain,'' ''problems with weight loss or wasting,'' or ''hair loss or changes in the way your hair looks.'' Responses to these items were extracted and combined to create a total score reflective of distress associated with appearance-related changes. For the current sample, internal consistency was a = .76.
Statistical analyses
The main analyses of the study, longitudinally examining the relationships between appearance concerns, depression severity, and ART non-adherence were conducted via linear mixed-effects modeling in PASW 18 (MIXED Procedure). The level-one variables represent the time variable (i.e., baseline, 3, 6, and 12 months post-baseline), in addition to other time-variant predictor variables: appearance concerns and depression severity, as well as timevariant covariates (CD4 count and viral load). Level-two variables included time-invariant covariates: study condition (CBT vs. TAU), age, and gender (see Table 2 for correlations among study variables). It should be noted that results did not significantly vary between adjusted and unadjusted models. Participants were treated as random effects, with random slopes and intercepts, whilst all remaining variables were fixed effects. In doing so, each participant was allowed to have a unique growth trajectory.
Further, the diagonal covariance structure was chosen based on the best goodness-of-fit (as evaluated by the Akaike Information Criterion-AIC), compared to competing covariance structures. The restricted maximum likelihood-REML-estimation method was chosen in lieu of maximum likelihood (ML) estimation, as the former approach tends to result in unbiased estimates of the variances and covariances (West, 2009 ).
Longitudinal mediation was tested via the Monte Carlo Method of Assessing Mediation (MCMAM; Bauer et al., 2006; MacKinnon et al., 2004) , which is a form of bootstrapping. Using the inputted parameter estimates and the associated standard errors, random draws from the a and b distributions are simulated and the product of these values is computed. This procedure is repeated a large number of times (i.e., 2,000) and the resulting distribution of the a * b values is used to estimate a 95 % confidence interval around the observed value of a * b. In doing so, the a * b path, or the indirect effect, allows one simple calculation to determine the presence of a mediated effect. The indirect (i.e., meditational) effect is interpreted as ''statistically significant'' if 0 is not contained between the lower and upper CIs. Bootstrapping methods are generally preferred over traditional methods of studying mediation (see Hayes, 2009; MacKinnon et al., 2004; Preacher & Hayes, 2008; Shrout & Bolger, 2002 ). In the current study, the MCMAM method was employed via software created by Selig and Preacher (2008) .
Results
Preliminary analyses explored appearance concerns, depression severity, and ART non-adherence independently, as a function of time. Results indicated that depression severity significantly declined over time, c = -.10, SE = .02, 95 % CI [-.13, -.06] , t = -6.3, p = .0001. ART non-adherence worsened over time, c = .68, SE = .30, 95 % CI [.08, 1.3], t = 2.2, p = .03. Conversely, The relationship between appearance concerns and depression severity (path a) emerged as significant, c = .31, SE = .076, 95 % CI [.16, .46] , t = 4.1, p = .0001, indicating that a one unit increase in appearance concerns was associated with a .31 increase in depression severity (on a 7-point scale). This finding indicates that reporting the highest level of appearance concerns compared to no appearance concerns corresponded to a 1.5 point increase in depression severity on the CGI (e.g., from a 3-''mildly depressed'' to a 5-''markedly depressed''). The path between depression severity and ART non-adherence (path b) was also significant, c = 3.3, SE = 1.3, 95 % CI [.8, 5 .8], t = 2.6, p = .01, indicating that a one unit increase in depression severity was associated with a 3.3 increase in ART nonadherence (on a 100-point scale). Finally, to test the mediational effect of depression severity in the relationship between appearance concerns and ART non-adherence, the indirect effect (a * b) was assessed via the MCMAM, which yielded a significant effect, c = 1.02, 95 % CI [.21, 2.1].
Discussion
Appearance concerns are prevalent among HIV-infected individuals, and are associated with increased depression (Blashill et al., 2012; Marín et al., 2006; Sharma et al., 2006 Sharma et al., , 2007 and ART non-adherence (Ammassari et al., 2002 , Duran et al., 2001 Glass et al., 2010; Plankey et al., 2009) . The findings from the current study revealed that among a depressed, opioid-dependent sample of HIVinfected men and women, the temporal relationship between appearance concerns and ART non-adherence was mediated by depression severity, even in a sample with elevated levels of depression, and hence a potentially restricted range, due to qualifying for a depressive diagnosis. Previous research in this area has largely relied on cross-sectional and/or self-report instruments and scant literature exist examining mechanisms behind the relationship between appearance concerns and ART nonadherence. Thus, the current study adds to the literature by providing a longitudinal mediational model with clinicianrated measures of distress and electronic monitoring of adherence.
Despite the additions to the literature the current study yields, several limitations are noted. Although the model in the current study was parsimonious and accounted for significant variance in ART non-adherence, more nuanced models should be also be explored. For instance, identifying the mechanisms and/or the conditions under which appearance concerns predict depression severity, as well as further exploring the link between depression severity and ART non-adherence would be important steps for future research. Further, while the CGI has been found to have strong convergent validity with other measures of depression, and CGI ratings were reviewed during supervision meetings with an independent rater, data on inter-rater reliability was not available. In addition, the current sample was exclusively comprised of HIV-infected individuals who were depressed, opioid-dependent, and largely heterosexual. Thus, findings may not translate to HIV-infected individuals who do not meet criteria for a depressive or opioid-dependent diagnosis, or men who have sex with men (MSM). However, cross-sectional research with gay and bisexual HIV-infected individuals has revealed similar findings (Blashill & Vander Wal, 2010) , although longitudinal research focusing on these associations among MSM is needed, especially considering that MSM are likely to experience elevated levels of appearance concerns (Morrison et al., 2004) . Also, the significant results of depression severity to non-adherence, even in a sample of individuals with pre-existing depression, speaks to the magnitude of this effect emerging even in the context of a possibly restricted range. An additional limitation was the assessment of ART adherence. A conservative window was applied in operationally defining non-adherence in the sample, a technique for which there is precedent (Applebaum et al., 2009; Safren et al., 2009 Safren et al., , 2012 . However, it is important to note that for modern ART regimens, there may be more flexibility with dosing time and a larger window may be used. Another limitation is the measurement of appearance concerns. Despite including three items, it did not assess specific body locations in regard to lipohypertrophy and lipoatrophy. There is preliminary evidence that, among women, abdominal hypertrophy is particularly related to ART non-adherence (Plankey et al., 2009) . Given this, future research should explicitly assess lipohypertrophy and lipoatrophy as a function of specific regions of the body in the context of ART non-adherence. Moreover, participants' perceived etiology of body changes were not assessed, and future research might examine individuals' attributions of ART to body morphology and the subsequent relationship with adherence. However, the association of appearance concerns to both depression severity and to non-adherence in the current study more generally speaks to the relevance of appearance among HIV-infected individuals as an important part of quality of life and managing a chronic medical illness.
The findings from the current study have the potential to inform clinical practice. Not only do appearance concerns create elevated levels of depression and anxiety (Blashill et al., 2012) , but as the results of the current study yield, through increased depression severity, predict ART non-adherence. ART non-adherence leads to disease progression and has increasingly become a concern for secondary prevention, as an individual with suppressed viral load confers significantly lower probability of transmitting HIV compared to those with a detectable viral load (Ambrosioni et al., 2011 , Cohen et al., 2011 . This is notable given that elevated levels of appearance concerns are associated with increased HIV sexual transmission risk behaviors (e.g., Wilton, 2009; Wingood et al., 2002 ).
An integrative cognitive behavioral intervention for depression and ART adherence (CBT-AD) has recently been developed and tested among HIV-infected populations (e.g., Safren et al., 2009 Safren et al., , 2012 . Generally, this intervention showed significant and sustained effects in reducing depressive symptoms, and at least acute effects on increasing ART adherence. Given that appearance concerns are common among HIV-infected individuals, and are prospectively associated with depression and ART non-adherence, researchers and clinicians should consider integrative interventions that not only address depression and ART adherence, but also explicitly address appearance concerns. Such interventions could not only have an impact on quality of life and depression, but also physical health and secondary HIV prevention.
